Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01195428
Other study ID # 15377
Secondary ID
Status Withdrawn
Phase N/A
First received September 2, 2010
Last updated January 6, 2014
Start date October 2010
Est. completion date October 2011

Study information

Verified date January 2014
Source University of Oklahoma
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Acute Lung Injury/Acute respiratory distress syndrome (ALI/ARDS) is a serious and frequently encountered entity in modern ICUs. Sepsis remains the most common cause of ALI/ARDS and carries the worst prognosis. The disease is characterized by an intense inflammatory process. This inflammation plays a major role in the development of gas exchange abnormalities seen in the course of the disease. Statins, primarily used as lipid-lowering agents, are now known to possess anti-inflammatory, antioxidant, antithrombogenic and vascular function-restoring actions. Therefore the investigators propose to determine if Simvastatin may be useful in decreasing the incidence of this deadly syndrome in critically ill patients.


Description:

Patients will be enrolled within 24 hours of ICU admission and randomized to 1 of 2 groups: Simvastatin or placebo. Patients' management will be entirely left up to the primary team, including the need for daily laboratory and imaging. In addition, there will be no restriction on the use of any medications, as deemed necessary by the primary care physician. The primary endpoint will be the incidence of ALI/ARDS. Secondary efficacy variables will be the number of days without organ or system failure, in addition to the change in IL-6, IL-8, and TNF- α. Treatment will continue until the primary endpoint is reached, the patient discharged from the ICU or the maximum duration of 2 weeks, whichever occurs first. Patients will continued to be followed for a total of 28 days, or until discharged from the hospital, whichever occurs first.

Patients randomized, in a ratio of 1:1 to either Simvastatin 40 mg PO once daily or placebo tablet once daily in a format identical to Simvastatin.

The mortality from ALI/ARDS remains significant. In the absence of effective therapy, prophylaxis in patients at risk is an important goal to achieve. Therefore, if Simvastatin is found to decrease the incidence of ALI/ARDS, it would be a significant advance in the management of this deadly and frequent syndrome.

We have set up a Data Safety Monitoring Board (DSMB) that will closely monitor the progress of the trial (DSMB Charter attached to this application). Any adverse event will be reported directly to the institutional review board (IRB) and DSMB. All adverse events will be reported in the annual review of the protocol.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults older than 18 years of age, admitted to the ICU with one or more of the following risk factors for ARDS/ALI:

- Sepsis, defined as the presence of infection-related systemic inflammatory response syndrome (SIRS).

SIRS is defined as the presence of two or more of the following:

- Temperature >38.5ºC or <35ºC

- Heart rate >90 beats/min

- Respiratory rate >20 breaths/min or PaCO2 <32 mmHg

- WBC >12,000 cells/mm3, <4000 cells/mm3, or >10 percent immature (band) forms

- Pneumonia, including community and health care associated pneumonias

- Aspiration, defined as the witnessed inhalation of gastric contents

- Acute pancreatitis

- Bilateral lung contusion

- Massive transfusion, defined as more than 15 units of red blood cells/24h

- Multiple (>2) long-bone fractures

Exclusion Criteria:

- Patients already on a statin

- Current indication for statin therapy according to the National guidelines

- NPO order

- Active liver disease, defined as ALT or AST > 3 times the upper limits of normal

- History of myopathy

- History of uncontrolled seizure disorder

- Pregnancy or breastfeeding

- Immunosuppressive therapy, including prednisone at dose > 10 mg/day

- Preexistent lung disease indicated by history or chest film

- High risk for cardiogenic pulmonary edema (defined as the presence of ventricular fibrillation, acute myocardial infarction, congestive heart failure with EF < 40%)

- High risk for neurogenic pulmonary edema (active CVA, or known increased intracranial pressure)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Simvastatin
Simvastatin 40 mg daily
Placebo
Placebo

Locations

Country Name City State
United States OU Medical Center Oklahoma City Oklahoma
United States Veterans Affairs Medical Center Oklahoma City Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
University of Oklahoma VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of ARDS/ALI. 4 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04247477 - Comparison of Different PEEP Titration Strategies Using Electrical Impedance Tomography in Patients With ARDS N/A
Completed NCT03315702 - Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins
Not yet recruiting NCT02693912 - Changes in Alveolar Macrophage Function During Acute Lung Injury N/A
Completed NCT01659307 - The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury Phase 2
Completed NCT01552070 - Recruitment on Extravascular Lung Water in Acute Respiratory Distress Syndrome (ARDS) Phase 2
Unknown status NCT01186874 - Epidemiology Research on Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) in Adult ICU in Shanghai N/A
Withdrawn NCT00961168 - Work of Breathing and Mechanical Ventilation in Acute Lung Injury N/A
Recruiting NCT00759590 - Comparison of Two Methods to Estimate the Lung Recruitment N/A
Completed NCT02475694 - Acute Lung Injury After Cardiac Surgery: Pathogenesis N/A
Completed NCT00736892 - Incidence of Acute Lung Injury: The Alien Study
Completed NCT00825357 - Biological Markers to Identify Early Sepsis and Acute Lung Injury N/A
Terminated NCT00263146 - Recruitment Maneuvers in ARDS: Effects on Respiratory Function and Inflammatory Markers. N/A
Completed NCT00188058 - Comparison of 2 Strategies of Adjustment of Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome N/A
Completed NCT00234767 - Study of the Economics of Pulmonary Artery Catheter Use in Patients With Acute Respiratory Distress Syndrome (ARDS) Phase 3
Recruiting NCT02598648 - Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates N/A
Recruiting NCT02948530 - Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods (Lungbarometry)
Completed NCT01532024 - Exploratory Clinical Study of Neutrophil Activation Probe (NAP) for Optical Molecular Imaging in Human Lungs Early Phase 1
Recruiting NCT01992237 - Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients N/A
Completed NCT01486342 - PET Imaging in Patients at Risk for Acute Lung Injury N/A